NERV
Price
$1.88
Change
+$0.08 (+4.44%)
Updated
Jun 16, 04:33 PM (EDT)
Capitalization
12.45M
56 days until earnings call
PRPO
Price
$10.88
Change
+$0.04 (+0.37%)
Updated
Jun 16, 03:19 PM (EDT)
Capitalization
9.51M
Interact to see
Advertisement

NERV vs PRPO

Header iconNERV vs PRPO Comparison
Open Charts NERV vs PRPOBanner chart's image
Minerva Neurosciences
Price$1.88
Change+$0.08 (+4.44%)
Volume$250
Capitalization12.45M
Precipio
Price$10.88
Change+$0.04 (+0.37%)
Volume$100
Capitalization9.51M
NERV vs PRPO Comparison Chart
Loading...
View a ticker or compare two or three
VS
NERV vs. PRPO commentary
Jun 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a StrongBuy and PRPO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 17, 2025
Stock price -- (NERV: $1.78 vs. PRPO: $10.89)
Brand notoriety: NERV and PRPO are both not notable
NERV represents the Biotechnology, while PRPO is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NERV: 45% vs. PRPO: 14%
Market capitalization -- NERV: $12.45M vs. PRPO: $9.51M
NERV [@Biotechnology] is valued at $12.45M. PRPO’s [@Medical Specialties] market capitalization is $9.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $356.66B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B. The average market capitalization across the [@Medical Specialties] industry is $8.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NERV’s FA Score shows that 0 FA rating(s) are green whilePRPO’s FA Score has 1 green FA rating(s).

  • NERV’s FA Score: 0 green, 5 red.
  • PRPO’s FA Score: 1 green, 4 red.
According to our system of comparison, PRPO is a better buy in the long-term than NERV.

Price Growth

NERV (@Biotechnology) experienced а -3.26% price change this week, while PRPO (@Medical Specialties) price change was -7.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.54%. For the same industry, the average monthly price growth was +9.91%, and the average quarterly price growth was +7.82%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.53%. For the same industry, the average monthly price growth was +0.81%, and the average quarterly price growth was +3.35%.

Reported Earning Dates

NERV is expected to report earnings on Aug 12, 2025.

PRPO is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Biotechnology (-2.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (-1.53% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

FUNDAMENTALS
Fundamentals
NERV($12.4M) has a higher market cap than PRPO($9.52M). PRPO YTD gains are higher at: 96.487 vs. NERV (-19.878). NERV has higher annual earnings (EBITDA): 8.58M vs. PRPO (-7.52M). NERV has more cash in the bank: 17.3M vs. PRPO (1.56M). NERV has less debt than PRPO: NERV (0) vs PRPO (1.3M). PRPO has higher revenues than NERV: PRPO (13.3M) vs NERV (0).
NERVPRPONERV / PRPO
Capitalization12.4M9.52M130%
EBITDA8.58M-7.52M-114%
Gain YTD-19.87896.487-21%
P/E Ratio2.20N/A-
Revenue013.3M-
Total Cash17.3M1.56M1,108%
Total Debt01.3M-
FUNDAMENTALS RATINGS
NERV vs PRPO: Fundamental Ratings
NERV
PRPO
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
5235
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRPO's Valuation (33) in the Biotechnology industry is in the same range as NERV (43). This means that PRPO’s stock grew similarly to NERV’s over the last 12 months.

PRPO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NERV (100). This means that PRPO’s stock grew similarly to NERV’s over the last 12 months.

PRPO's SMR Rating (95) in the Biotechnology industry is in the same range as NERV (100). This means that PRPO’s stock grew similarly to NERV’s over the last 12 months.

PRPO's Price Growth Rating (35) in the Biotechnology industry is in the same range as NERV (52). This means that PRPO’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as PRPO (100). This means that NERV’s stock grew similarly to PRPO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIEZX21.61N/A
N/A
JPMorgan International Equity R2
GIDHX8.00N/A
N/A
Goldman Sachs Intl Eq Div & Prem Instl
QISCX25.56N/A
N/A
Federated Hermes MDT Small Cap Core IS
MSECX10.86N/A
N/A
Morgan Stanley Inst International Eq C
UIVMX12.12N/A
N/A
MFS Intrinsic Value R1

NERV and Stocks

Correlation & Price change

A.I.dvisor tells us that NERV and CVAC have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NERV and CVAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-1.11%
CVAC - NERV
32%
Poorly correlated
-0.90%
DNLI - NERV
32%
Poorly correlated
+0.48%
ANAB - NERV
32%
Poorly correlated
+2.49%
PLRX - NERV
30%
Poorly correlated
-1.45%
RCKT - NERV
30%
Poorly correlated
-1.71%
More

PRPO and Stocks

Correlation & Price change

A.I.dvisor tells us that PRPO and APDN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PRPO and APDN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRPO
1D Price
Change %
PRPO100%
+0.32%
APDN - PRPO
27%
Poorly correlated
+9.52%
VTAK - PRPO
27%
Poorly correlated
-5.48%
TNON - PRPO
27%
Poorly correlated
+0.24%
CSTL - PRPO
26%
Poorly correlated
+2.77%
TIVC - PRPO
25%
Poorly correlated
+1.08%
More